3 February 2012 - US Idenix Pharmaceuticals Inc (NASDAQ:IDIX) said today that the FDA has lifted the partial clinical hold on IDX184 and that its 12-week Phase IIb trial assessing IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV) may continue.

IDX184, the firm's lead product candidate for the treatment of hepatitis C virus (HCV) infection is a pan-genotypic oral nucleotide polymerase inhibitor, and has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.

Recently reported interim Phase IIb data showed favourable antiviral activity and no serious adverse events.